Search Publications
Search
Found 448 matches. Displaying 1 - 10
[ 1 - 10 | Next ]
1. Guselkumab binding to CD64<SUP>+</SUP> IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling FRONTIERS IN IMMUNOLOGY 2025 MAR 12; 16(?):? Article 1532852 Full Text | PMID/PMCID
2. Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1 JOURNAL OF INVESTIGATIVE DERMATOLOGY 2025 MAR; 145(3):? Full Text | PMID/PMCID
3. Hepatocyte Growth Factor Has Unique Functions in Keratinocytes that Differ from those of IL-17A and TNF and May Contribute to Inflammatory Pathways in Hidradenitis JOURNAL OF INVESTIGATIVE DERMATOLOGY 2025 MAR; 145(3):? Full Text | PMID/PMCID
4. Single-cell transcriptomic analysis of GPP patients treated with IL-12/23 or IL-17A blockade JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 2025 2025 MAR 25; ?(?):? Full Text | PMID/PMCID
5. Skin immune-mesenchymal interplay within tertiarylymphoid structures promotes autoimmunepathogenesis in hidradenitis suppurativa IMMUNITY 2024 DEC 10; 57(12):? Full Text | PMID/PMCID
6. The Impact of Melanoma Imaging Biomarker Cues on Detection Sensitivity and Specificity in Melanoma versus Clinically Atypical Nevi CANCERS 2024 SEP; 16(17):? Article 3077 Full Text | PMID/PMCID
7. Eosinophils in hidradenitis suppurativa patients exhibit pro-inflammatory traits, implicating a potential pathogenic role in the disease EXPERIMENTAL DERMATOLOGY 2024 JUL; 33(7):? Article e15129 Full Text | PMID/PMCID
8. The interferon-rich skin environment regulates Langerhans cell ADAM17 to promote photosensitivity in lupus ELIFE 2024 JUN 11; 13(?):? Article e85914 Full Text | PMID/PMCID
9. Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood ALLERGY 2024 2024 JUL 14; ?(?):? Full Text | PMID/PMCID
10. Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial DERMATOLOGY AND THERAPY 2024 2024 SEP 16; ?(?):? Full Text | PMID/PMCID
[ 1 - 10 | Next ]